On November 9th, Fruquintinib, a new anti-tumor drug independently developed by Hutchison Pharmaceutical (China) Co., Ltd., was approved by the US Food and Drug Administration (FDA) and entered the local pharmaceutical market, becoming the first and only highly selective inhibitor approved for all three anti-vascular endothelial growth factor (VEGF) receptors in the United States for the treatment of metastatic colorectal cancer. This is the second successful case of small molecule anticancer drugs independently developed by China, and it is also the second biomedical product sold overseas and developed in Shanghai this year.
On October 29th, Loqtorzi, the PD-1 monoclonal antibody independently developed by Shanghai Junshi Biomedical Technology Co., Ltd. was approved by FDA for marketing, marking the first victory of innovative biomedical drugs developed and produced by China and sold abroad. This is another milestone since Loqtorzi became the first PD-1 antibody drug independently developed in China. It announced that the Chinese treatment protocol for nasopharyngeal carcinoma has been recognized by international authorities, which is expected to set a new standard for the global treatment protocol for nasopharyngeal carcinoma.
In recent years, Shanghai has taken many measures to encourage its enterprises to "bring in" and "go out" to face the vast global market. In the next step, the city will continue to play the role of leading group for industrial development, continuously optimize policies and services in biomedical innovation research and development, industrial transformation, commercialization, and international cooperation and exchanges, create a world-class industrial development ecology, and help more competitive independent innovation products go global for the benefit of all mankind.
